Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long COIN Daily ETF vs Gilead Sciences, Inc. — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5 (market cap $534.51M), while Gilead Sciences, Inc. trades at $147 (market cap $182.09B). The key difference: Gilead Sciences, Inc. is far larger — about 340.7× GraniteShares 2x Long COIN Daily ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while GraniteShares 2x Long COIN Daily ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and Gilead Sciences, Inc. for 111 Days on average.
| CONL | GILD | |
|---|---|---|
Market Cap | $534.51M | $182.09B |
Volume | 15,212,221 | 4,960,247 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $155.80 |
52-Week Low | $3.93 | $116.74 |
Typical Hold Time | 15 Days | 111 Days |
Enterprise Value | — | $205.15B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONL (GraniteShares 2x Long COIN Daily ETF) is trading at $5.23, down 7.76% with bearish technical signals from moving averages. The ETF tracks Coinbase stock with 2x daily leverage, making it highly volatile. Recent news highlights significant price gaps and performance volatility, with one article noting an 85% decline when Coinbase fell 50%.
The outlook remains high-risk due to leveraged exposure to Coinbase volatility. Investment opportunity exists for speculative traders betting on Coinbase rebounds, but risks include amplified losses, tracking error, and crypto market sentiment swings. Caution is warranted given the bearish technical setup and leveraged structure.
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
